Regeneron Pharmaceuticals, Inc. (BMV:REGN)
Mexico · Delayed Price · Currency is MXN 10,480
+5 (0.05%)
At close: Aug 8, 2025, 2:00 PM CST
CTI BioPharma Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Net Income | 4,459 | 4,413 | 3,954 | 4,338 | 8,075 | 3,513 | Upgrade |
Depreciation & Amortization | 510.1 | 482.9 | 421 | 341.4 | 286.2 | 235.9 | Upgrade |
Asset Writedown & Restructuring Costs | 12.6 | 12.6 | - | 195 | - | - | Upgrade |
Loss (Gain) From Sale of Investments | -311.7 | -118.3 | 266.4 | 36.8 | -387 | -221.8 | Upgrade |
Stock-Based Compensation | 1,037 | 982.8 | 885 | 725 | 601.7 | 432 | Upgrade |
Other Operating Activities | -714.4 | -733.8 | -837.9 | -378.4 | 421.6 | 162.4 | Upgrade |
Change in Accounts Receivable | 122.9 | -554 | -338.8 | 707.8 | -1,927 | -1,356 | Upgrade |
Change in Inventory | -476.9 | -619.7 | -271.7 | -696.5 | -494.3 | -529.4 | Upgrade |
Change in Accounts Payable | 422.3 | 735.1 | 598.6 | -138.4 | 866.1 | 118.9 | Upgrade |
Change in Unearned Revenue | -103.4 | 227.8 | 37.9 | 32.4 | -120.2 | 148.1 | Upgrade |
Change in Other Net Operating Assets | -213.5 | -407.5 | -120.1 | -148.6 | -240.7 | 114.9 | Upgrade |
Operating Cash Flow | 4,744 | 4,421 | 4,594 | 5,015 | 7,081 | 2,618 | Upgrade |
Operating Cash Flow Growth | 16.53% | -3.78% | -8.39% | -29.18% | 170.47% | 7.74% | Upgrade |
Capital Expenditures | -889.8 | -755.9 | -718.6 | -590.1 | -551.9 | -614.6 | Upgrade |
Sale of Property, Plant & Equipment | - | 20.1 | - | - | - | - | Upgrade |
Cash Acquisitions | -11.5 | -16.5 | -54.9 | -230.3 | - | - | Upgrade |
Sale (Purchase) of Intangibles | -297.4 | -125.7 | -207.8 | -1,027 | - | - | Upgrade |
Investment in Securities | 528.4 | -1,590 | -2,204 | -1,937 | -4,833 | 544 | Upgrade |
Investing Cash Flow | -670.3 | -2,468 | -3,185 | -3,785 | -5,385 | -70.6 | Upgrade |
Short-Term Debt Issued | - | - | - | - | - | 1,500 | Upgrade |
Long-Term Debt Issued | - | - | - | - | - | 1,982 | Upgrade |
Total Debt Issued | - | - | - | - | - | 3,482 | Upgrade |
Short-Term Debt Repaid | - | - | - | - | - | -1,500 | Upgrade |
Total Debt Repaid | - | - | - | - | - | -1,500 | Upgrade |
Net Debt Issued (Repaid) | - | - | - | - | - | 1,982 | Upgrade |
Issuance of Common Stock | 437.7 | 1,465 | 1,146 | 1,520 | 1,672 | 2,575 | Upgrade |
Repurchase of Common Stock | -4,195 | -3,632 | -2,936 | -2,529 | -2,678 | -6,528 | Upgrade |
Other Financing Activities | -43.7 | -33.4 | - | - | - | - | Upgrade |
Financing Cash Flow | -3,987 | -2,201 | -1,790 | -1,009 | -1,006 | -1,971 | Upgrade |
Foreign Exchange Rate Adjustments | 1.1 | -0.7 | -0.4 | - | - | - | Upgrade |
Net Cash Flow | 87.4 | -248.8 | -381.6 | 221.3 | 690.8 | 577 | Upgrade |
Free Cash Flow | 3,854 | 3,665 | 3,875 | 4,425 | 6,529 | 2,004 | Upgrade |
Free Cash Flow Growth | 15.77% | -5.44% | -12.42% | -32.23% | 225.90% | 0.15% | Upgrade |
Free Cash Flow Margin | 27.11% | 25.80% | 29.54% | 36.35% | 40.63% | 23.58% | Upgrade |
Free Cash Flow Per Share | 34.29 | 31.84 | 34.08 | 38.98 | 58.19 | 17.41 | Upgrade |
Cash Interest Paid | 52.6 | 52.6 | 73.1 | 53.7 | 55.8 | 23.2 | Upgrade |
Cash Income Tax Paid | 743 | 743 | 870.3 | 1,502 | 1,218 | 188.1 | Upgrade |
Levered Free Cash Flow | 2,851 | 2,636 | 2,763 | 2,628 | 4,309 | 1,192 | Upgrade |
Unlevered Free Cash Flow | 2,874 | 2,670 | 2,808 | 2,665 | 4,345 | 1,227 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.